Intellipharmaceutics International Inc. Quarterly Comprehensive Income (Loss), Net of Tax, Attributable to Parent in USD from Q1 2013 to Q3 2023

Taxonomy & unit
us-gaap: USD
Description
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
Summary
Intellipharmaceutics International Inc. quarterly/annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent history and growth rate from Q1 2013 to Q3 2023.
  • Intellipharmaceutics International Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the quarter ending August 31, 2023 was -$1.89M, a 538% decline year-over-year.
  • Intellipharmaceutics International Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2015 was -$7.44M, a 92.8% decline from 2014.
  • Intellipharmaceutics International Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2014 was -$3.86M, a 64.8% increase from 2013.
  • Intellipharmaceutics International Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2013 was -$11M, a 75.2% decline from 2012.
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Quarterly (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2023 -$1.89M -$1.59M -538% Jun 1, 2023 Aug 31, 2023 6-K 2023-10-16
Q2 2023 -$54.1K +$787K +93.6% Mar 1, 2023 May 31, 2023 6-K 2023-09-26
Q3 2022 -$296K Jun 1, 2022 Aug 31, 2022 6-K 2023-10-16
Q2 2022 -$841K Mar 1, 2022 May 31, 2022 6-K 2023-09-26
Q1 2014 $2.2M +$3.3M Dec 1, 2013 Feb 28, 2014 6-K 2014-04-14
Q1 2013 -$1.1M Dec 1, 2012 Feb 28, 2013 6-K 2014-04-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.